5.3 Genetic Risk Assessment & Family History Counseling

Pedigree Construction & Standardized Family History Analysis

A meticulously constructed family pedigree serves as the primary clinical genetic screening instrument in ambulatory family medicine. Systematic collection of family history enables clinicians to stratify patient risk, identify monogenic hereditary syndromes, tailor cancer surveillance protocols, and initiate life-saving cascade genetic testing.

The 3-Generation Pedigree

A comprehensive pedigree must encompass at least three generations of biological relatives:

1. First-Degree Relatives (FDRs): Parents, full siblings, and biological children (share 50% of genetic material on average).
2. Second-Degree Relatives (SDRs): Grandparents, aunts, uncles, nieces, nephews, grandchildren, and half-siblings (share 25% of genetic material).
3. Third-Degree Relatives (TDRs): First cousins, great-grandparents, and great-grandchildren (share 12.5% of genetic material).

Standardized Pedigree Nomenclature & Symbols

• Geometric Symbols: Square = Male; Circle = Female; Diamond = Sex unspecified/unknown.
• Status Indicators: Filled / Shaded Symbol = Affected with clinical disease/phenotype; Half-Filled Symbol = Heterozygous carrier of an autosomal recessive gene or X-linked trait; Diagonal Slash = Deceased individual; Arrow pointing to symbol with 'P' = Proband (the index patient presenting for clinical evaluation).
• Relationship Lines: Horizontal line connecting a male and female = Mating/relationship; Double horizontal line = Consanguinity (mating between blood relatives, strongly increasing risk of autosomal recessive disorders); Vertical line descending from mating line = Biological offspring (arranged chronologically from left to right by birth order).
• Essential Clinical Annotations: For every relative, record current age (or age at death and cause of death), specific cancer or disease diagnoses, exact age at primary diagnosis, tumor anatomical location/laterality, and relevant environmental exposures (e.g., heavy tobacco use).

Red Flags for Hereditary Cancer Syndromes: The "PREDISPOSE" Framework

Clinicians should immediately recognize classic clinical hallmarks of hereditary cancer syndromes:

• P - Premature Onset: Cancer diagnosed at an unusually early age (e.g., colorectal, breast, or endometrial cancer diagnosed before age 50).
• R - Rare Tumors: Identification of unusual neoplasms (e.g., male breast cancer, medullary thyroid cancer, pheochromocytoma, adrenocortical carcinoma, diffuse gastric cancer, sebaceous adenomas).
• E - Excessive Polyposis: Presence of >10 to 20 cumulative adenomatous colorectal polyps.
• D - Dual / Multiple Primaries: Synchronous or metachronous primary cancers in a single individual (e.g., bilateral breast cancer; colorectal cancer plus synchronous endometrial cancer).
• I - Inherited Pattern: Autosomal dominant transmission pattern across multiple successive generations (vertical transmission affecting males and females alike).
• S - Specific Syndromic Clusters: Constellations of biologically linked tumors (e.g., breast-ovarian-pancreatic-prostate clustering; colorectal-endometrial-ovarian-gastric clustering).
• P - Pathognomonic Non-Malignant Features: Physical stigmata such as macrocephaly and mucocutaneous trichilemmomas (Cowden syndrome), mucosal melanin pigmentation of the lips and buccal mucosa (Peutz-Jeghers syndrome), or congenital hypertrophy of the retinal pigment epithelium (CHRPE in FAP).
• O - Origin / Ancestry: Specific ethnic ancestry associated with founder mutations (e.g., Ashkenazi Jewish ancestry, which carries a 1 in 40 carrier frequency for BRCA1/2 mutations compared to 1 in 400 in the general population).
• S - Several Affected Relatives: Two or more first- or second-degree relatives with the same or related tumor types.
• E - Exact Histology: High-grade serous ovarian cancer, triple-negative breast cancer, or microsatellite-unstable (MSI-High) colorectal tumors.

---

Hereditary Breast & Ovarian Cancer Syndrome (HBOC - BRCA1 & BRCA2)

Molecular Genetics & Cancer Penetrance

HBOC is an autosomal dominant condition caused by germline loss-of-function mutations in the tumor suppressor genes BRCA1 (chromosome 17q21) or BRCA2 (chromosome 13q12). Both genes encode large nuclear proteins essential for the homologous recombination repair (HRR) pathway that repairs DNA double-strand breaks.

• Lifetime Malignancy Risks in Mutation Carriers:
  • Female Breast Cancer: 60% to 80% lifetime risk (often diagnosed premenopausally; BRCA1 cancers are predominantly triple-negative [estrogen receptor-negative, progesterone receptor-negative, HER2-negative], whereas BRCA2 cancers are frequently hormone receptor-positive).
  • Ovarian / Fallopian Tube / Primary Peritoneal Cancer: 40% to 50% lifetime risk for BRCA1; 10% to 20% lifetime risk for BRCA2 (predominantly high-grade serous carcinoma arising in the fimbriated end of the fallopian tube).
  • Male Breast Cancer: ~7% to 8% lifetime risk in BRCA2 carriers (only 1% to 2% in BRCA1).
  • Prostate Cancer: 20% to 25% lifetime risk in male BRCA2 carriers, characterized by aggressive, high-Gleason score pathology and early metastatic progression.
  • Pancreatic Adenocarcinoma: 3% to 5% lifetime risk in both BRCA1 and BRCA2.
  • Cutaneous Melanoma: Significantly elevated relative risk primarily associated with BRCA2 mutations.

USPSTF Grade B Recommendations for BRCA Screening

The U.S. Preventive Services Task Force recommends (Grade B) that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer, or who have an ancestry associated with BRCA1/2 gene mutations, using a validated familial risk assessment tool:

• Validated Screening Instruments: Ontario Family History Assessment Tool (FHAT), Manchester Scoring System, BRCAPRO, Tyrer-Cuzick (IBIS model), and the Pedigree Assessment Tool (PAT).
• Clinical Workflow:
  1. Women whose screening assessment is positive should receive pre-test genetic counseling conducted by a certified genetic counselor or trained genetics professional.
  2. If indicated following formal counseling and shared decision-making, the patient should undergo targeted or multi-gene panel genetic testing.
  3. If a pathogenic or likely pathogenic variant is identified, cascade genetic testing is offered to all at-risk biological relatives.
• USPSTF Grade D Warning: The USPSTF explicitly recommends against routine genetic counseling or testing for women whose personal or family history is not associated with an increased risk for pathogenic BRCA1/2 variants (Grade D recommendation).

Clinical Management of BRCA Mutation Carriers

• Intensive Breast Surveillance:
  • Annual contrast-enhanced breast MRI beginning at age 25 (or 5 to 10 years before the earliest familial breast cancer diagnosis).
  • Add annual mammography (digital breast tomosynthesis) beginning at age 30, alternating modalities every 6 months (e.g., breast MRI in January, mammography in July).
• Risk-Reducing Bilateral Salpingo-Oophorectomy (RRBSO):
  • Recommended at age 35 to 40 for BRCA1 carriers, and age 40 to 45 for BRCA2 carriers (or upon completion of childbearing).
  • Reduces ovarian/fallopian tube cancer risk by >80% to 90% and reduces all-cause mortality. Board pearl: Routine ovarian cancer screening with transvaginal ultrasound and serum CA-125 is NOT effective, fails to detect early-stage ovarian cancer, and is NOT recommended as a substitute for RRBSO.
• Risk-Reducing Bilateral Mastectomy: Reduces invasive breast cancer risk by >90% to 95%.
• Male Carrier Protocols: Annual clinical breast examination starting at age 35; annual PSA screening starting at age 40 for BRCA2 carriers.

---

Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer / HNPCC)

Molecular Pathophysiology & DNA Mismatch Repair

Lynch syndrome is the most prevalent hereditary colorectal cancer syndrome, accounting for 3% to 5% of all colorectal carcinomas. It is an autosomal dominant condition caused by germline mutations in one of four DNA Mismatch Repair (MMR) genes:

• MLH1 (chromosome 3p21) and MSH2 (chromosome 2p21): Account for ~70% to 80% of all Lynch syndrome mutations (highest penetrance).
• MSH6 and PMS2: Lower penetrance, often presenting with later-onset colorectal or endometrial cancers.
• EPCAM Deletions: Deletions in the EPCAM gene (upstream of MSH2) cause epigenetic hypermethylation and transcriptional silencing of the intact MSH2 promoter.
• Mechanism: DNA MMR proteins proofread newly synthesized DNA strands and correct base-base mismatches and insertion-deletion loops that occur during replication. Loss of MMR function leads to failure of DNA slippage repair, producing Microsatellite Instability (MSI-High) throughout the genome and accelerating the adenoma-carcinoma sequence from the usual 10 to 15 years down to 2 to 3 years.

Clinical Malignancy Spectrum

• Colorectal Cancer (CRC): 50% to 80% lifetime risk. Characteristically exhibits proximal / right-sided colon predominance (cecum and ascending colon in >70%), poorly differentiated or medullary histology, mucinous features, and abundant tumor-infiltrating lymphocytes.
• Endometrial Cancer: 40% to 60% lifetime risk in women. Critical Board Pearl: Endometrial carcinoma is frequently the sentinel cancer in female Lynch carriers, preceding colorectal cancer diagnosis by several years!
• Extracolonic Malignancies: Ovarian cancer (10–12%), gastric cancer (5–10%), small bowel adenocarcinoma (duodenum/jejunum, 4–7%), urothelial carcinoma of the renal pelvis and ureter (2–10%), hepatobiliary cancer (2–4%), glioblastoma multiforme (Turcot syndrome variant), and sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas (Muir-Torre syndrome variant).

Clinical Diagnostic Criteria: The Amsterdam II Criteria

The classic clinical diagnostic criteria for Lynch syndrome are remembered by the "3-2-1 Rule":

• 3 or more relatives with a confirmed Lynch-associated cancer (colorectal, endometrial, small bowel, ureter/renal pelvis).
• Involving at least 2 successive generations.
• At least 1 affected relative is a first-degree relative of the other two.
• At least 1 cancer diagnosed before age 50.
• Familial adenomatous polyposis (FAP) has been excluded.
• Tumors verified by pathological review.

Universal Tumor Testing: The Revised Bethesda Guidelines & Modern Standard of Care

While the Revised Bethesda Guidelines historically guided which colorectal tumors should undergo testing, current national guidelines (NCCN, AGA, ASCO) mandate Universal Reflex Screening: ALL newly diagnosed colorectal and endometrial cancers, regardless of patient age or family history, must undergo screening for mismatch repair deficiency.

• Reflex Testing Workflow:
  1. Perform Immunohistochemistry (IHC) for the 4 MMR proteins (MLH1, MSH2, MSH6, PMS2) and/or Microsatellite Instability (MSI) testing via PCR on tumor biopsy tissue.
  2. If MSH2, MSH6, or PMS2 proteins are absent on IHC, the patient is directly referred for germline genetic testing.
  3. If MLH1 protein expression is absent, the loss is usually due to sporadic, non-hereditary somatic promoter hypermethylation. To differentiate sporadic cancer from Lynch syndrome, the tumor must undergo testing for the BRAF V600E somatic mutation and MLH1 promoter hypermethylation:
     • Presence of BRAF V600E mutation OR presence of MLH1 promoter hypermethylation = Sporadic colon cancer (rules out Lynch syndrome; no germline testing required).
     • Absence of BRAF mutation AND absence of promoter hypermethylation = High suspicion for germline Lynch syndrome; proceed directly to germline MLH1 sequencing.

Surveillance & Risk-Reduction Protocols for Lynch Syndrome

• Colorectal Surveillance: High-quality colonoscopy every 1 to 2 years, beginning at age 20 to 25 (or 2 to 5 years prior to the earliest colorectal cancer diagnosed in the family if diagnosed before age 25). The 1- to 2-year interval is mandatory because the adenoma-carcinoma transition is markedly accelerated.
• Gynecologic Surveillance & Prophylaxis: Annual endometrial biopsy and transvaginal ultrasound may be considered starting at age 30 to 35, but has limited diagnostic sensitivity. The definitive recommendation is risk-reducing total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) after completion of childbearing (typically at age 40 to 45).
• Upper Gastrointestinal Surveillance: Esophagogastroduodenoscopy (EGD) with baseline biopsy for Helicobacter pylori every 2 to 4 years starting at age 35 to 40.

---

Familial Adenomatous Polyposis (FAP) & Polyposis Syndromes

Molecular Genetics & Phenotypic Manifestations

Familial Adenomatous Polyposis is an autosomal dominant condition with near 100% penetrance, caused by germline mutations in the APC (Adenomatous Polyposis Coli) tumor suppressor gene located on chromosome 5q21. Approximately 25% of cases arise from de novo germline mutations in individuals without a family history.

• Classic FAP:
  • Characterized by the progressive emergence of hundreds to thousands (typically >100 to >1,000) of adenomatous colorectal polyps carpeting the colon and rectum, beginning in adolescence (ages 10 to 15).
  • Colorectal Cancer Penetrance: If untreated, the progression of polyps to invasive colorectal adenocarcinoma is nearly 100% by age 40 to 50.
• Attenuated FAP (AFAP):
  • Characterized by 10 to 99 adenomatous polyps, predominantly located in the right/proximal colon, with a later onset of polyps and delayed colorectal cancer progression (mean age of cancer diagnosis ~55 years).
• Extracolonic Manifestations of FAP:
  • Duodenal & Ampullary Adenomas: Occur in >90% of FAP patients; periampullary duodenal adenocarcinoma is the second leading cause of cancer-related mortality in FAP.
  • Gastric Fundic Gland Polyps: Present in >50% of patients; low malignant potential.
  • Desmoid Tumors: Locally aggressive, non-metastasizing monoclonal fibroblastic proliferations arising in the abdominal wall and mesentery in 10% to 15% of patients. Desmoids represent a major cause of post-colectomy morbidity and mortality due to mesenteric vessel encasement and bowel obstruction.
  • Congenital Hypertrophy of the Retinal Pigment Epithelium (CHRPE): Bilateral, discrete, pigmented retinal lesions observed on dilated funduscopic exam in >75% of classic FAP patients. CHRPE is asymptomatic and does not cause vision loss, but serves as a pathognomonic clinical marker for FAP in at-risk children.
  • Osteomas & Soft Tissue Tumors: Benign osteomas of the mandible and skull, epidermoid cysts, and dental abnormalities (Gardner syndrome).
  • Central Nervous System Tumors: Medulloblastomas associated with FAP (Turcot syndrome).

Surveillance & Surgical Management Protocols

• Colorectal Surveillance: Annual flexible sigmoidoscopy or colonoscopy starting at age 10 to 12 years for classic FAP (or age 18 to 20 for AFAP).
• Prophylactic Surgery: Total proctocolectomy with ileal pouch-anal anastomosis (IPAA), or total abdominal colectomy with ileorectal anastomosis (IRA). Surgery is typically performed in late adolescence or early adulthood (ages 18 to 25) when the polyp burden becomes too dense for endoscopic management or when severe dysplasia arises.
• Upper GI Surveillance: Forward- and side-viewing upper endoscopy (EGD) starting at age 25 to 30 to stage duodenal adenomas using the Spigelman staging system.

---

Hereditary Cardiomyopathies: Hypertrophic Cardiomyopathy (HCM)

Molecular Genetics & Pathophysiology

Hypertrophic Cardiomyopathy is an autosomal dominant condition of variable expressivity and incomplete penetrance caused by pathogenic mutations in cardiac sarcomere protein genes. The two most common causative genes are:

• MYH7 (beta-myosin heavy chain): Accounts for ~30% to 40% of identified mutations.
• MYBPC3 (cardiac myosin-binding protein C): Accounts for ~30% to 40% of identified mutations.
• Pathological Hallmark: Disorganized myofibrillar architecture ("myocardial fiber disarray"), marked myocyte hypertrophy, interstitial fibrosis, and asymmetrical left ventricular hypertrophy (most commonly involving the basal anterior interventricular septum). HCM is the single most common cause of sudden cardiac death (SCD) in young athletes under age 35.

Dynamic Auscultation & Hemodynamics (High-Yield Board Concept)

Patients typically present with dynamic Left Ventricular Outflow Tract (LVOT) obstruction caused by septal hypertrophy combined with Systolic Anterior Motion (SAM) of the mitral valve, which makes contact with the septum during midsystole, producing both LVOT obstruction and mitral regurgitation.

• Auscultation: Harsh, crescendo-decrescendo systolic ejection murmur heard best at the left lower sternal border (without radiation to the carotid arteries).
• Dynamic Bedside Maneuvers:
  • Maneuvers that INCREASE Murmur Intensity: Maneuvers that decrease left ventricular preload or decrease afterload reduce left ventricular end-diastolic volume, narrowing the LVOT and exacerbating obstruction:
    • Valsalva Maneuver (strain phase) (decreases venous return / preload).
    • Sudden Standing from a squatting position (decreases venous return / preload).
    • Administration of nitrates or dihydropyridine calcium channel blockers (reduces preload/afterload).
  • Maneuvers that DECREASE Murmur Intensity: Maneuvers that increase left ventricular preload or increase afterload expand the left ventricular chamber, widening the LVOT and relieving obstruction:
    • Passive Leg Raise (increases venous return / preload).
    • Squatting (increases venous return and systemic vascular resistance).
    • Sustained Handgrip (increases systemic vascular resistance / afterload).

Cascade Family Screening Guidelines

• All first-degree relatives of an individual diagnosed with HCM should undergo cascade genetic testing if the proband's causative sarcomeric mutation has been identified.
• If genetic testing in the family is negative, inconclusive (variant of uncertain significance), or declined, first-degree relatives must undergo serial clinical screening with a 12-lead ECG and transthoracic echocardiogram (TTE):
  • Children and adolescents (ages 12 to 18): Every 1 to 2 years.
  • Adults (age ≥18): Every 3 to 5 years (or immediately if clinical symptoms of chest pain, dyspnea, presyncope, or palpitations emerge).

---

Hereditary Hemochromatosis (HH)

Molecular Genetics & Pathophysiology

Hereditary Hemochromatosis is an autosomal recessive disorder of systemic iron metabolism characterized by uninhibited intestinal iron absorption. More than 85% to 90% of clinical cases in individuals of Northern European descent result from homozygosity for the C282Y mutation (p.Cys282Tyr) in the HFE gene located on chromosome 6p21.3. Less commonly, patients are compound heterozygotes for C282Y / H63D.

• Molecular Mechanism: The normal HFE protein binds the transferrin receptor-1 (TfR1) on hepatocytes, signaling circulating iron levels to induce the transcription of hepcidin (the master iron-regulatory hormone). The C282Y mutation prevents HFE cell-surface expression, causing severe deficiency of hepcidin. Without hepcidin, the basolateral iron exporter ferroportin remains constitutively active on duodenal enterocytes and reticuloendothelial macrophages, pumping toxic amounts of iron into the plasma, saturating transferrin, and depositing non-transferrin-bound iron into parenchymal tissues.

Clinical Manifestations: The Classic "Bronze Diabetes" Triad

Clinical symptoms typically emerge between ages 40 and 60 in men; women present on average 10 to 15 years later due to physiological blood and iron losses through menstruation and childbearing.

• Liver: Hepatomegaly, elevated transaminases, progressive bridging fibrosis, micronodular cirrhosis, and a 20- to 200-fold increased relative risk of hepatocellular carcinoma (HCC).
• Endocrine: "Bronze Diabetes": Iron deposition in pancreatic beta cells leads to diabetes mellitus. Deposition in the anterior pituitary gland causes hypogonadotropic hypogonadism, presenting as testicular atrophy, loss of libido, and erectile dysfunction in men, and amenorrhea in women.
• Skin: Diffuse slate-gray or hyperpigmented "bronze" skin discoloration resulting from combined melanin and hemosiderin deposition.
• Musculoskeletal / Arthropathy: Progressive, chronic degenerative arthropathy characteristically localized to the second and third metacarpophalangeal (MCP) joints and wrists. Plain radiographs demonstrate chondrocalcinosis (calcium pyrophosphate dihydrate / pseudogout), joint space narrowing, and characteristic squared-off bone margins with hook-like osteophytes.
• Cardiac: Dilated cardiomyopathy, restrictive cardiomyopathy, conduction system disease, and supraventricular arrhythmias.

Diagnostic Evaluation & Screening Cascade

1. Initial Biochemical Screening: Fasting Transferrin Saturation (TSAT) and Serum Ferritin.
   • Fasting TSAT ≥45% (or ≥50% in men) is the single most sensitive initial phenotypic screening test for hemochromatosis.
   • Serum ferritin reflects total body iron storage. Ferritin is also an acute-phase reactant; therefore, an isolated high ferritin with normal TSAT warrants evaluation for alcohol use, MASLD, infection, or chronic inflammation.
2. Confirmatory Genetic Testing: If fasting TSAT ≥45% and ferritin is elevated, perform targeted HFE mutation analysis for C282Y and H63D.
3. Assessing Hepatic Fibrosis & Cirrhosis Risk:
   • Serum Ferritin >1,000 mcg/L OR elevated serum AST/ALT indicates a high risk for advanced hepatic fibrosis or cirrhosis; these patients mandate hepatic elastography, liver MRI (T2* quantification of hepatic iron content), or a percutaneous liver biopsy to evaluate for cirrhosis and establish the need for lifelong hepatocellular carcinoma surveillance.

Therapeutic Phlebotomy & Clinical Prognosis

• Induction Phase: Therapeutic phlebotomy (removal of 1 unit [500 mL] of whole blood, removing ~200 to 250 mg of elemental iron) performed weekly or biweekly.
  • Target Induction Endpoint: Continue phlebotomy until serum ferritin reaches 50 to 100 mcg/L and TSAT is <50%.
• Maintenance Phase: Lifelong maintenance phlebotomy (typically 1 unit every 2 to 4 months) to sustain ferritin between 50 and 100 mcg/L.
• High-Yield Clinical Pearl on Phlebotomy Outcomes:
  • Phlebotomy reverses lethargy, normalizes elevated transaminases, halts the progression of early hepatic fibrosis, reverses dilated cardiomyopathy, and improves glycemic control.
  • Hemochromatosis Arthropathy (MCP joint pain) typically DOES NOT improve with therapeutic phlebotomy; joint pain frequently persists or paradoxically worsens despite complete iron depletion, requiring treatment with NSAIDs or joint arthroplasty.

---

Master Comparative Table of High-Yield Hereditary Syndromes

---

The Genetic Information Nondiscrimination Act (GINA) of 2008

The Genetic Information Nondiscrimination Act (GINA) was enacted by the United States Congress to address public fears that predictive genetic testing results could be weaponized by insurers or employers. Understanding the exact statutory boundaries of GINA is a frequent, high-yield topic on the ABFM board examination.

Legal Protections Granted Under GINA

GINA defines "genetic information" expansively to include an individual's genetic test results, the genetic test results of family members, family medical history (up to fourth-degree relatives), and participation in clinical genetic research or genetic counseling. GINA provides robust protections across two specific domains:

1. Health Insurance Protections (Title I):
   • Group health plans, private individual health insurance policies, and Medicare supplemental policies cannot use genetic information to determine eligibility, underwriting, or premium rates.
   • Health insurers cannot classify genetic information as a pre-existing condition in the absence of manifest, diagnosed disease.
   • Health insurers are strictly prohibited from demanding, requesting, or requiring that an individual or their family members undergo genetic testing.
2. Employment Protections (Title II):
   • Employers with 15 or more employees, employment agencies, labor organizations, and joint labor-management training programs cannot use genetic information in decisions concerning hiring, firing, job assignments, promotions, layoffs, or compensation.
   • Employers are prohibited from requesting, requiring, or purchasing genetic information regarding an employee or their family members.

Critical Statutory Limitations & Board Exam Pitfalls

Clinicians must clearly communicate the critical gaps in GINA protections to patients considering predictive genetic testing:

• GINA Explicitly Does NOT Apply to Other Insurance Underwriting:
  • Life Insurance: Life insurance companies CAN legally request genetic test results, consider family history, adjust premiums, or deny life insurance coverage based on pathogenic variants (e.g., BRCA1, Lynch syndrome, Huntington disease).
  • Disability Insurance: Disability underwriters can legally deny policies or charge higher premiums based on genetic test results.
  • Long-Term Care Insurance: Long-term care insurance underwriters are exempt from GINA and can use genetic test results during underwriting.
• Exempted Employment & Military Populations:
  • Employers with fewer than 15 employees are exempt from GINA Title II.
  • Active-Duty Military Personnel (TRICARE) and the military healthcare system are not covered by GINA (governed by internal Department of Defense regulations).
  • The Veterans Health Administration (VHA), Indian Health Service (IHS), and Federal Employees Health Benefits Program (FEHB) are exempt from GINA, though separate executive orders provide parallel protections for federal civilian employees.
• Manifest Symptomatic Illness vs. Asymptomatic Genetic Predisposition:
  • GINA protects against discrimination based on predictive genetic predisposition or family history in an asymptomatic individual.
  • Critical Distinction: Once an individual develops clinically manifest, diagnosed, symptomatic disease (e.g., a patient carrying BRCA1 who is diagnosed with invasive breast cancer, or a patient with HFE C282Y who has biopsy-proven cirrhosis), GINA no longer applies to the clinical diagnosis. Patient protections against health insurance discrimination based on active, manifest pre-existing conditions fall under the Affordable Care Act (ACA), and workplace disability accommodations fall under the Americans with Disabilities Act (ADA).